We concluded that similarly to CIITA, EZH2, and CREBBP mutations (6–8), IRF8 variants may add to the pathogenesis of B cell lymphomas by impairing antigen presentation in the context of MHCII. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.